John Gunderman
Tampa, FLNPI 1861513640
Payments from drug & device makers
$1,908in general payments, 2019–2025
Across 179 payments — averaging $10.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$324
- Corium, LLC$285
- Supernus Pharmaceuticals, Inc.$272
- UCB, Inc.$263
- Eisai Inc.$164
- Takeda Pharmaceuticals U.S.A., Inc.$145
- plus $454 from 8 others
What the payments were for
- Food & beverage$1,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
21
22
23
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 72 | $324 |
| Corium, LLC | 17 | $285 |
| Supernus Pharmaceuticals, Inc. | 35 | $272 |
| UCB, Inc. | 14 | $263 |
| Eisai Inc. | 9 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $145 |
| Neurelis, Inc. | 8 | $134 |
| Neos Therapeutics, LP | 5 | $92 |
| Tris Pharma Inc | 4 | $77 |
| Adlon Therapeutics L.p. | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DepakoteDivalproex Sodium | 12 | $4,937 |
| Clonidine Hcl | 20 | $153 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.